Data capture is no longer the bottleneck, and whether the lag between a signal and a decision shrinks depends on signal design, AI governance, and vendor orchestration.
|Articles|May 19, 2016
PAREXEL Opens North American Facilities in PA
Advertisement
PAREXEL recently opened a state-of-the-art North American Coordination Hub and Distribution Center in Pennsylvania-marking an expanded presence in the region. The facility, located in Quakertown, will provide customers around the world with clinical trial supplies and logistics services designed to reduce study start-up planning and accelerate first patient-in. The North American Coordination Hub and Distribution Center can:
- Provide-local and/or central sourcing of comparator and non-investigational medicinal products
- Coordinate investigational medicinal products manufacturing through contract manufacturing organization or sponsor-delegated partners to optimize material utilization, supply and re-supply strategies, expiration dates and costs
- Offer full-service and secondary clinical packaging for randomized, double-blind or two/three panel studies, as well as customized packaging design, custom secondary packaging and patient supply kits
- Develop, translate and distribute all the documentation for sites, investigators or patients
Advertisement
Related to this article
In this Q&A, Rajneesh Patil, global head of AI, digital, and innovation in clinical development at Syneos Health, discusses what changes when AI is embedded across protocol strategy, data infrastructure, and workflow tools at once, where governance frameworks tend to fall short, and why CROs must orchestrate AI ecosystems rather than simply aggregate them.
In today’s ACT Brief, we examine what policy changes would help community and rural institutions join research, how Walmart is expanding clinical trial centers into three more states, and how FDA approved Ilumya for adults with active psoriatic arthritis.
The planned sites in Livonia, Las Vegas, and San Antonio would expand a partnership that places clinical research and health screenings inside Walmart stores.
In this video interview, Kent Thoelke, CEO of Paradigm Health, calls for safe harbor protections, CMS reimbursement safeguards, and funding mechanisms modeled on EHR meaningful use to help community and rural institutions participate in research on par with academic centers.
In today’s ACT Brief, we examine why community and rural patients lack access to research as a care option, what makes AI assistants trustworthy in regulated trials, and how FDA draft guidance could let gene editing therapies cover patient-specific variants.
In this Q&A, E.K. Koh, chief product officer at Suvoda, discusses what separates a trustworthy AI assistant from one that adds risk, why curated clinical knowledge matters more than general-purpose flexibility, and what safeguards must be in place when assistants move from answering questions to taking actions in clinical trial systems.
In this video interview, Kent Thoelke, CEO of Paradigm Health, explains why patients in community and rural settings too often lack access to clinical research as a care option, and how closing that gap could improve outcomes and lower long-term costs.
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Building AI Assistants Clinical Trial Teams Can Trust: Q&A with E.K. Koh, Suvoda
2
From Signal to Action: Why Faster Trial Data Isn’t Producing Faster Decisions
3
What Needs to Happen Beyond the Clinical Trial Modernization Act
4
Walmart and Care Access Plan Three More Clinical Trial Centers in Michigan, Nevada, and Texas
5